Concord Biotech Limited
Book Built Issue IPO · NSE, BSE
- Price band
- ₹705 - ₹741
- Lot size
- 20 shares
- Issue amount
- ₹1,551 cr
- Total subscription
- 26.13×
- Opens
- 4 Aug 2023
- Closes
- 8 Aug 2023
- Allotment
- 14 Aug 2023
- Listing
- 18 Aug 2023
Offer at a glance
Issue overview
- Issue size
- 2,09,25,652 shares
- Face value
- ₹1 Per Share
- Minimum investment
- ₹14,100
- Fresh issue
- ₹0 cr
- Offer for sale
- ₹1,551 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,820
- Issue type
- Book Built Issue IPO
- Shares before issue
- 0
- Shares after issue
- 10,46,16,204
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 20 | ₹14,820 |
| sHNI | 14 | 280 | ₹2,07,480 |
| bHNI | 68 | 1,360 | ₹10,07,760 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 294.91 | 20,975.08 |
| RETAIL | 516.09 | 2,050.34 |
| NIB | 221.18 | 3,949.83 |
| HNIs 2+ | 73.73 | 958.56 |
| HNIs 10+ | 147.46 | 2,991.27 |
| EMPLOYEES | 0.7 | 18.13 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Values |
|---|---|
| EPS | 20.79 |
| ROE | 20.06 |
| ROCE | 24.27 |
| RONW | 20 |
| PRE IPO(PE) | 32.29 |
| POST IPO(PE) | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Incorporated in 1984, Concord Biotech Limited is an India-based biopharmaceutical company and a leading global developer and manufacturer of fermentation-based APIs, specializing in immunosuppressants and oncology. The company has a strong global presence, supplying products to over 70 countries including the USA, India, Europe, and Japan. Concord Biotech manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Starting with a single product, the company has expanded to offer a broad spectrum of biopharma solutions, establishing itself as a key player in the global API market.
Promoters
Mr. Sudhir Vaid
Mr. Ankur Vaid
Registrar & documents
Lead manager
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Jefferies India Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
1482-86, Trasad Road Dholka, Ahmedabad – 382225
079-6813 8700
[email protected]Company website ↗Understanding CONCORDBIO IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.